Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC for liver transplantation (LT). Atezolizumab-bevacizumab (atezo-bev) can induce objective responses in nearly one-third of patients; however, the role and outcomes of downstaging using atezo-bev remains unknown.
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: